Blueprint Medicines Reports Second Quarter 2024 Results and Raises AYVAKIT®/AYVAKYT® (avapritinib) Full Year Revenue Guidance

FREE Breaking News Alerts from StreetInsider.com!

E-mail Address

StreetInsider.com Top Tickers, 6/22/2026

1. SPCX
2. NVDA
3. ACN
4. USO
5. DFTX
6. GOOGL
7. APGE
8. MU
9. HOOD
10. IBM

Go back to Blueprint Medicines Reports Second Quarter 2024 Results and Raises AYVAKIT®/AYVAKYT® (avapritinib) Full Year Revenue Guidance

Blueprint Medicines (BPMC) PT Raised to $155 at Stifel

August 1, 2024 12:14 PM EDT

Stifel analyst Bradley Canino raised the price target on Blueprint Medicines (NASDAQ: BPMC) to $155.00 (from $150.00) while maintaining a Buy rating.

The analyst comments "A 13% Ayvakit beat and 11% increase to the FY24 Ayvakit guidance midpoint is fundamentally positive, but for today at least... More